RxDoctor Payments Data

Lucian Szmyd, MD

Ophthalmology · Portsmouth, NHNPI 1376548149

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2023 at $503 and has fallen 91.8% since, to $41 in 2025.

$1,758in general payments, 2019–2025

Across 60 payments — averaging $29.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$491
  • Glaukos Corporation$460
  • Aerie Pharmaceuticals, Inc.$181
  • Sun Pharmaceutical Industries Inc.$119
  • Novartis$98
  • Ocular Therapeutix, Inc.$98
  • plus $310 from 9 others

What the payments were for

  • Food & beverage$1,63593%
  • Education$402%
  • Gifts$845%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,758 in reported general payments places this provider in the 55th percentile of 80 ophthalmology providers in New Hampshire.

See all ophthalmology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$341,071
Medicare patients
1,022
Services billed
2,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost42$22,595
Travoprost29$8,712
CombiganBrimonidine Tartrate/Timolol19$8,133
Alphagan PBrimonidine Tartrate13$6,754
Timolol Maleate270$5,127
Brimonidine Tartrate60$4,310
Latanoprost290$4,306
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$3,875
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat80$2,590
Prednisolone Acetate60$2,588
Tobramycin-DexamethasoneTobramycin/Dexamethasone28$1,456
Dorzolamide Hcl68$1,099
Ketorolac Tromethamine15$398
MoxifloxacinMoxifloxacin Hcl12$339
ErythromycinErythromycin Base11$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$491$37,48274 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 80 ophthalmology providers in New Hampshire.

Other ophthalmology in Portsmouth

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →